कंपनी का अवलोकन
Celcuity Inc. operates as a clinical-stage biotechnology enterprise primarily dedicated to the development of targeted therapies for the treatment of various solid tumors within the United States. The company functions within the broader Healthcare sector, specifically specializing in the Biotechnology industry, which implies a focus on high-risk, high-reward research and development activities aimed at advancing medical treatments. Celcuity maintains a market capitalization of $6.02B, employs a workforce of 155 individuals, and reports revenue figures that are currently not available for the trailing twelve months. The substantial market capitalization of $6.02B indicates that the market holds significant value expectations for the company's pipeline, despite the absence of reported annual revenue, suggesting the valuation is heavily driven by potential future commercialization of its lead drug candidate, Gedatolisib, rather than current operational cash flows.
वित्तीय स्वास्थ्य
Celcuity reports a net income of $-177,042,000 and an EBITDA of $-172,024,992 over the trailing twelve months, while revenue and price-to-sales data are not available. The significant gap between the reported net income loss and the EBITDA figure reveals a cost structure where non-operating expenses, such as interest or other financial charges, are contributing substantially to the bottom-line deficit, as the difference between the two metrics is approximately $5 million. The company generates a free cash flow of $-96,047,504, indicating a substantial cash outflow that reflects heavy investment in research and development and operational scaling rather than profitability. All three key margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, which indicates that the company is currently in a pre-revenue or early-stage development phase where traditional profitability measures have not yet been realized. On the balance sheet, Celcuity holds $441.50M in cash against $321.90M in debt, resulting in a debt-to-equity ratio of 320.13, which suggests a highly leveraged financial position relative to its equity base. However, the current ratio stands at 10.55, indicating strong short-term liquidity and the ability to cover short-term obligations many times over with existing current assets. Return on Equity is -163.8% and Return on Assets is -30.2%, metrics that reveal management is currently generating negative returns on the capital invested, a common characteristic for clinical-stage biotechnology firms burning cash to advance their therapeutic candidates through clinical trials.
मूल्यांकन आकलन
The trailing twelve-month P/E ratio is listed as N/A due to negative earnings, while the forward P/E stands at -113.31, implying that the market is pricing in future earnings that are not yet realized or are expected to be negative in the near term. The price-to-book ratio is 59.81, indicating a massive market premium over the company's book value, which is typical for biotechnology firms where intangible assets like drug candidates are valued far above their accounting book value. The price-to-sales ratio is N/A and the EV/EBITDA is -34.33, suggesting that traditional multiple-based valuation methods are difficult to apply given the lack of sales and negative earnings. The stock has traded between a 52-week low of $7.58 and a 52-week high of $124.63, with the current price position relative to this range dependent on the specific trading day but historically exhibiting extreme volatility within this spread. The beta value is 0.42, which means the stock's price volatility is significantly lower than the broader market, suggesting it may be less sensitive to general market movements despite its high valuation multiples.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, meaning there is no historical data to compare current performance against to determine if earnings are growing faster or slower than revenue. As a non-dividend payer, the company offers a dividend yield of N/A and a payout ratio of 0.0%, indicating that all available cash is being reinvested into the business operations and research rather than distributed to shareholders. The absence of a dividend payout ratio confirms that the company is retaining earnings to fund its clinical trials and development costs rather than providing income to investors. The overall growth and income profile for Celcuity is characterized by zero current income generation and undefined growth rates due to the clinical-stage status of its primary assets, focusing entirely on capital appreciation potential rather than dividend yields.